Phase 1 trial of KMA.CAR-T for kappa-type multiple myeloma
Latest Information Update: 27 Jul 2023
At a glance
- Drugs KMA CAR T (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors HaemaLogiX
Most Recent Events
- 27 Jul 2023 New trial record
- 25 Jul 2023 According to a HaemaLogiX media release, the company has have entered a collaboration agreement with Peter MacCallum Cancer Centre to develop and conduct this trial. Under the agreement, HaemaLogiX brings its patented KappaMab technology to the collaboration with Peter Mac to develop the technology, method of manufacturing and conduct the trial.